Chimeric anti-CD25 monoclonal antibody for treating acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
- VernacularTitle:嵌合型CD25单抗治疗造血干细胞移植术后急性移植物抗宿主病
- Author:
Jingzhi WANG
;
Kaiyan LIU
;
Lanping XU
;
Daihong LIU
;
Yuhong CHEN
;
Xiaojun HUANG
- Publication Type:Journal Article
- Keywords:
Anti-CD2 monoclonal antibody;
Graft vs host disease;
Stem cell transplantation
- From:
Chinese Journal of Internal Medicine
2008;47(11):923-925
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of chimeric anti-CD2 monoclonal antibody (basiliximab) on acute graft-versus-host disease (GVHD) in patients following aliogeneic hematopoietic stem cell transplantation. Methods Thirty-six patients who were suffered from acute GVHD from March 2005 to July 2007 were studied. All of them were treated with steroid first and got no response, then began basiliximab therapy. Results Thirty of 36 patients showed response to basiliximab therapy including 25 complete responses and 5 partial responses. The efficacy was associated with the degree of GVHD and the source of donor. Conclusion Patients suffered from steroid-resistant acute GVHD can be successfully treated with basiliximab.
